Blueprint Medicines (NASDAQ:BPMC) Issues Quarterly Earnings Results, Beats Estimates By $0.49 EPS

Blueprint Medicines (NASDAQ:BPMC) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($1.29) by $0.49, Briefing.com reports. Blueprint Medicines had a negative net margin of 102.15% and a negative return on equity of 193.48%. The firm had revenue of $138.20 million during the quarter, compared to analyst estimates of $104.02 million. During the same quarter last year, the business posted ($2.19) EPS. The company’s revenue for the quarter was up 139.9% on a year-over-year basis.

Blueprint Medicines Trading Down 3.6 %

Shares of Blueprint Medicines stock opened at $96.72 on Friday. The company’s 50-day moving average price is $108.75 and its 200-day moving average price is $97.09. The company has a current ratio of 3.76, a quick ratio of 3.61 and a debt-to-equity ratio of 0.67. Blueprint Medicines has a 12-month low of $43.89 and a 12-month high of $121.90. The company has a market cap of $6.06 billion, a price-to-earnings ratio of -20.11 and a beta of 0.63.

Insider Activity at Blueprint Medicines

In other Blueprint Medicines news, insider L. Becker Hewes sold 4,922 shares of the stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $106.43, for a total value of $523,848.46. Following the sale, the insider now directly owns 31,938 shares in the company, valued at approximately $3,399,161.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider L. Becker Hewes sold 4,922 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $106.43, for a total transaction of $523,848.46. Following the completion of the transaction, the insider now directly owns 31,938 shares in the company, valued at $3,399,161.34. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Debra Durso-Bumpus sold 74,034 shares of the firm’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $104.19, for a total value of $7,713,602.46. Following the completion of the sale, the insider now directly owns 43,763 shares in the company, valued at approximately $4,559,666.97. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 130,064 shares of company stock valued at $13,716,726. Corporate insiders own 4.21% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. HC Wainwright increased their price target on Blueprint Medicines from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Friday, May 3rd. StockNews.com raised Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Friday, May 3rd. Guggenheim boosted their price target on shares of Blueprint Medicines from $130.00 to $138.00 and gave the stock a “buy” rating in a report on Friday. Stephens assumed coverage on shares of Blueprint Medicines in a report on Tuesday, May 14th. They set an “overweight” rating and a $140.00 price objective for the company. Finally, The Goldman Sachs Group lifted their price objective on shares of Blueprint Medicines from $121.00 to $168.00 and gave the stock a “buy” rating in a research report on Monday, May 6th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Blueprint Medicines currently has a consensus rating of “Moderate Buy” and an average target price of $120.00.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.